In a trial of kidney transplant recipients who received the α-BAFF mAb belimumab in an effort to decrease de novo IgG production and limit allograft rejection, MEM B cell numbers were not different between the belimumab-treated and control groups (92). The gene discussed is TNFSF13B; the disease is medical procedure.